Radiotherapy plus hormone therapy cut prostate cancer mortality by more than half

Potters, Louis
October 2008
Hem/Onc Today;10/25/2008, Vol. 9 Issue 19, p20
The article discusses a research which reported the efficiency of radiotherapy plus antiandrogen therapy in reducing disease-specific mortality in patients with prostate cancer. The results of the study were presented by Anders Widmark, professor of radiation oncology at Umea University in Sweden, at the 50th Annual Meeting of the American Society for Therapeutic Radiology and Oncology. It indicates the prostate-specific antigen recurrence rate in the hormone therapy arm and in the combination arm. Patient-evaluated adverse events are mentioned.


Related Articles

  • Novel Drug Shows Promise for CRPC. Schieszer, John // Renal & Urology News;Sep2009, Vol. 8 Issue 9, p20 

    The article presents a study on the treatment of men with castration-resistant prostate cancer (CRPC) in Orlando, Florida. It notes that the study found out that a novel antiandrogen with unique properties has the potential to benefit men with castration-resistant prostate cancer (CRPC). It adds...

  • A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Parker, C.; Muston, D.; Melia, J.; Moss, S.; Dearnaley, D. // British Journal of Cancer;5/22/2006, Vol. 94 Issue 10, p1361 

    The lead time and over-detection associated with prostate-specific antigen (PSA) screening, and generational improvements in all-cause mortality, make prostate cancer outcome studies from the pre-PSA era difficult to interpret in a contemporary setting. We developed a competing-risks hazard...

  • Radiotherapy plus hormone therapy halved prostate cancer mortality.  // Hem/Onc Today;3/10/2014, Vol. 15 Issue 5, p24 

    The article discusses research being done on the addition of radiation therapy to anti-androgen therapy for patients with prostate cancer, which references a study by Sophie Dorothea Fosså et al. presented at the 2014 Genitourinary Cancers Symposium in San Francisco, California.

  • Interval Cancers in Prostate Cancer Screening: Comparing 2- and 4-Year Screening Intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam. Roobol, Monique J.; Grenabo, Anna; Schröder, F-rtz H.; Hugosson, Jonas // JNCI: Journal of the National Cancer Institute;9/5/2007, Vol. 99 Issue 17, p1296 

    Background The incidence of prostate cancer has increased substantially since it became common practice to screen asymptomatic men for the disease. The European Randomized Study of Screening for Prostate Cancer (ERSPC) was initiated in 1993 to determine how prostate-specific antigen (PSA)...

  • Düşük prostat spesifik antijen deÄŸeri olan hastalara yapılan transrektal prostat biyopsi sonuçları. Bodakçi, Mehmet Nuri; Bozkurt, Yaşar; Atar, Murat; Hatipoğlu, Namık Kemal; Penbegül, Necmettin; Söylemez, Haluk; Sancaktutar, Ahmet Ali; Yıldırım, Kadir // Dicle Medical Journal / Dicle Tip Dergisi;2012, Vol. 39 Issue 2, p238 

    Objectives: The aim of this study is to evaluate the results of prostate biopsy of patients who had the prostatespecific antigen (PSA) levels below 4 ng/ml. Material and methods: The medical records of 63 patients who underwent transrectal prostate biopsy, between January 2005 and December 2011,...

  • Prostate Cancer: Monitor or Treat?  // HEALTHWire Senior Health Topics;Jan2017, p1 

    The article reports on an increase in number of patients with prostate cancer in the U.S. found by Prostate Testing for Cancer and Treatment (ProtecT) trial. Topics discussed include using Prostate-Specific Antigen (PSA) test followed by a biopsy to diagnose early stage prostate, side effects of...

  • Is there an anti-androgen withdrawal syndrome for enzalutamide? Klot, Christoph; Kramer, Mario; Böker, Alena; Herrmann, Thomas; Peters, Inga; Kuczyk, Markus; Ligges, Uwe; Gschwend, Jürgen; Retz, Margitta; Schmid, Sebastian; Stenzl, Arnulf; Schwentner, Christian; Todenhöfer, Tilmann; Stöckle, Michael; Ohlmann, Carsten-Henning; Azone, Ines; Mager, René; Bartsch, Georg; Haferkamp, Axel; Heidenreich, Axel // World Journal of Urology;Oct2014, Vol. 32 Issue 5, p1171 

    Background: The anti-androgen withdrawal syndrome (AAWS) can be seen in one-third of patients after discontinuation of first-generation non-steroidal anti-androgen therapy. With the introduction of new agents for anti-androgen therapy as well as alternate mechanisms of action, new therapeutic...

  • Relationship between two year PSA nadir and biochemical recurrence in prostate cancer patients treated with iodine-125 brachytherapy. da Silva Franca, Carlos Antônio; Vieira, Sérgio Lannes; Carvalho, Antonio Carlos Pires; Bernabe, Antonio Jose Serrano; Penna, Antonio Belmiro Rodrigues Campbell // Radiologia Brasileira;Mar/Apr2014, Vol. 47 Issue 2, p89 

    Objective: To evaluate the relationship between two year PSA nadir (PSAn) after brachytherapy and biochemical recurrence rates in prostate cancer patients. Materials and Methods: In the period from January 1998 to August 2007, 120 patients were treated with iodine-125 brachytherapy alone. The...

  • Can Prostate-Specific Antigen Kinetics before Prostate Biopsy Predict the Malignant Potential of Prostate Cancer? Sang Jin Kim; Tae Yoong Jeong; Dae Seon Yoo; Jinsung Park; Seok Cho; Seok Ho Kang; Sang Hyub Lee; Seung Hyun Jeon; Tchun Yong Lee; Sung Yul Park // Yonsei Medical Journal;Nov2015, Vol. 56 Issue 6, p1492 

    Purpose: To predict the malignant potential of prostate cancer (PCa) according to prostate-specific antigen velocity (PSAV), PSA density (PSAD), free/total PSA ratio (%fPSA), and digital rectal examination (DRE). Materials and Methods: From January 2009 to December 2012, 548 adult male patients...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics